Kurt Baeten

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Arnon P. Kater, Carolyn Owen, Carol Moreno et al. · NEJM Evidence · 2022 · 208 citations

Immunology, Pathology, Fixed-duration Ibrutinib-venetoclax +16

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

David Lorente, David Olmos, Joaquı́n Mateo et al. · European Urology · 2016 · 153 citations · Full text

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Carsten Utoft Niemann, Talha Munir, Carol Moreno et al. · The Lancet Oncology · 2023 · 117 citations

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia +10

Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma

Evelyne Louis, Peter Adriaensens, Wanda Guedens et al. · Journal of Thoracic Oncology · 2016 · 77 citations

Biomarker (Medicine), Oncology, Cancer Detection +12

Unlocking the Potential of Saliva-Based Test to Detect HPV-16-Driven Oropharyngeal Cancer

Kai Dun Tang, Kurt Baeten, Liz Kenny et al. · Cancers · 2019 · 54 citations · Full text